Page 5 - Patrick Lu News Today

Phase I clinical trial expected to initiate in second quarter 2022 HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they have received the "safe to proceed" letter from the U.S. Food and Drug Administration (FDA) for the Company's...

HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. , a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for... | February 9, 2022

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, June 16, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases, and other unmet clinical indications, today annou...

Published: Apr 29, 2021   GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 29, 2021 /PRNewswire/ -- Sirnaomics (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases and viral infections, announced today that the company has entered into a partnership agreement with Walvax Biotechnology (Walvax) for the co-development of its anti-influenza siRNA therapeutic product can...

Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 29, 2021 /PRNewswire/ -- Sirnaomics Biopharmaceuticals (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases and viral infections, announced today that the company has entered into a partnership agreement with Walvax Biotechnology (Walvax) for the co-development of its anti-influenza siR...

Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer Company Expects to Report Initial Clinical Data in Second Half of 2021 News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 25, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of the Phase 2b study of the...